Was macht X4 Pharmaceuticals?
Unternehmensprofil
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Chart der X4 Pharmaceuticals Aktie
Charttool öffnen
Aktuelle Nachrichten zu X4 Pharmaceuticals
Weitere Nachrichten
Das berichten andere über X4 Pharmaceuticals
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor)
Wir finden für unsere Leser softwaregestützt die besten Aktien der Welt
und schreiben darüber, wie man diese handeln muss, um Geld zu verdienen.